for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Perrigo Company PLC

PRGO.N

Latest Trade

44.78USD

Change

-0.84(-1.84%)

Volume

194,730

Today's Range

44.41

 - 

45.83

52 Week Range

40.12

 - 

63.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
45.62
Open
45.80
Volume
194,730
3M AVG Volume
17.63
Today's High
45.83
Today's Low
44.41
52 Week High
63.55
52 Week Low
40.12
Shares Out (MIL)
136.48
Market Cap (MIL)
6,226.20
Forward P/E
--
Dividend (Yield %)
1.97

Next Event

Q3 2020 Perrigo Company PLC Earnings Call

Latest Developments

More

Perrigo Voluntarily Recalls Albuterol Sulfate Inhalation Aerosol

Sol Gel Technologies Collaboration Partner Filed First-To-File Paragraph IV Certification For Duobrii

Perrigo Acquires Market-Leading Otc Self-Care Brands In Eastern Europe

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Perrigo Company PLC

Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the United States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with generic consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.

Industry

Personal Services

Contact Info

The Sharp Building, Hogan Place

D02 TY74

Ireland

+353.1.7094000

https://www.perrigo.com/

Executive Leadership

Murray S. Kessler

President, Chief Executive Officer, Director

Raymond P. Silcock

Chief Financial Officer, Executive Vice President

Robert Willis

Chief Human Resource Officer, Executive Vice President

Thomas M. Farrington

Executive Vice President, Chief Information Officer

James E. Dillard

Executive Vice President, Chief Scientific Officer

Key Stats

2.45 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

4.9K

2018

4.7K

2019

4.8K

2020(E)

5.1K
EPS (USD)

2017

4.930

2018

4.550

2019

4.030

2020(E)

4.060
Price To Earnings (TTM)
26.07
Price To Sales (TTM)
1.23
Price To Book (MRQ)
1.05
Price To Cash Flow (TTM)
9.84
Total Debt To Equity (MRQ)
70.09
LT Debt To Equity (MRQ)
59.83
Return on Investment (TTM)
2.41
Return on Equity (TTM)
2.04

Latest News

Latest News

BRIEF-Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg

* ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES

BRIEF-Perrigo Says Terminated Existing Credit Agreements

* PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT

BRIEF-Perrigo - John Hendrickson's 2017 Total Compensation $8.3 Million Versus $5.8 Million In 2016

* PERRIGO COMPANY PLC CEO JOHN HENDRICKSON'S 2017 TOTAL COMPENSATION $8.3 MILLION VERSUS $5.8 MILLION IN 2016 - SEC FILING

BRIEF-Perrigo CEO Buys 7,500 Shares Of Co's Ordinary Shares On March 5

* PERRIGO CEO UWE ROEHRHOFF REPORTS PURCHASE OF 7,500 SHARES OF CO'S ORDINARY SHARES ON MARCH 5 - SEC FILING Source text: (http://bit.ly/2Fpn04Z) Further company coverage:

BRIEF-Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand OTC Equivalent Of Mucinex DM Maximum Strength Extended Release Tablets

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF MUCINEX® DM MAXIMUM STRENGTH EXTENDED RELEASE TABLETS

BRIEF-Perrigo Company Q4 GAAP Earnings Per Share $0.52

* REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS

BRIEF-Perrigo Company Reports Select Preliminary Unaudited 2017 Financial Results

* REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS

BRIEF-Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%

* PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF FINACEA® FOAM, 15%

BRIEF-Perrigo Appoints Ronald Winowiecki As CFO

* PERRIGO APPOINTS RONALD L. WINOWIECKI AS CHIEF FINANCIAL OFFICER

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra Cream, 1%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF SOOLANTRA® CREAM, 1% Source text for Eikon: Further company coverage:

BRIEF-Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace Cream

* PERRIGO ANNOUNCES FINAL FDA APPROVAL OF A GENERIC VERSION OF ESTRACE CREAM

BRIEF-Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo Gel

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND LAUNCH OF AN AB RATED GENERIC VERSION OF EPIDUO GEL Source text for Eikon: Further company coverage:

BRIEF-Perrigo Says In Connection With Uwe Röhrhoff's Appointment As CEO, Co's Unit Perrigo DAC Entered Into Employment Agreement With Him

* PERRIGO COMPANY - IN CONNECTION WITH UWE RÖHRHOFF'S APPOINTMENT AS CEO, CO'S UNIT PERRIGO DAC ENTERED INTO AN EMPLOYMENT AGREEMENT WITH HIM

Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO

Generic drugmaker Perrigo Company Plc appointed Uwe Rohrhoff, former CEO of Gerresheimer AG, as its new chief executive, the company said on Monday.

Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO

Generic drugmaker Perrigo Company Plc appointed former Gerresheimer AG Chief Executive Uwe Rohrhoff as its new president and CEO, the company said on Monday.

BRIEF-Perrigo appoints Uwe Röhrhoff as CEO

* PERRIGO APPOINTS UWE RÖHRHOFF AS PRESIDENT & CHIEF EXECUTIVE OFFICER

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF PROLENSA® OPHTHALMIC SOLUTION 0.07% Source text for Eikon: Further company coverage:

BRIEF-Perrigo Announces The Launch Of An AB Rated Generic Version Of Mycolog II Cream

* PERRIGO ANNOUNCES THE LAUNCH OF AN AB RATED GENERIC VERSION OF MYCOLOG II CREAM Source text for Eikon: Further company coverage:

BRIEF-Perrigo Company ‍Launch AB Rated Generic Version Of Exalgo 32mg

* PERRIGO COMPANY PLC - LAUNCH OF AN AB RATED GENERIC VERSION OF EXALGO 32MG EXTENDED RELEASE TABLETS C-II Source text for Eikon: Further company coverage:

BRIEF-Perrigo Company completes divestiture of API business for $110 million

* Perrigo Company completes divestiture of API business for $110 million Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up